SIDEBAR: Is G13D KRAS Mutational Status Ready for Prime Time?


Get Permission

Axel Grothey, MDIndividual oncologists will have to decide for themselves whether the results from the pooled analysis of cetuximab trials regarding G13D KRAS mutational status are ready for clinical application, according to Axel Grothey, MD, of the Mayo Clinic in Rochester, Minnesota.

“We still need confirmatory data,” Dr. Grothey commented. In fact, a similar analysis of trials using the anti-EGFR antibody panitumumab (Vectibix) could soon be presented at an international meeting. In the meantime, “do I utilize [anti-EGFR therapy] in my clinical practice when I have a patient with G13D mutation? Yes, I do…if I see I am running out of options,” he said. “I’m not going to use EGFR antibodies as first-line therapies in these patients, but… [I might use them] in the last-line setting,” Dr. Grothey said.

Other Health-care Systems

Charles D. Blanke, MDMeeting Chair Charles D. Blanke, MD, of the University of British Columbia in Canada, pointed out that the calculus might differ in other health-care systems.

“Using anti-EGFR antibodies in G13D mutant disease seems like a reasonable thing to do if patients are paying for it or even if it is diffused among insurance companies and payers,” he elaborated. “In our case, we have to decide whether to fund it or not for the province of British Columbia. [Our protocols are] evidence-based, and we have a limited pie…. So the question is, should we fund it now? Is the evidence strong enough?”

“No, not yet,” Dr. Grothey replied, noting the some of the reported study’s analyses were based on small numbers of patients. “I’d like to see the data from the panitumumab trials.” (Editor’s note: Watch future issues of The ASCO Post for coverage of the panitumumab trials from the European Multidisciplinary Cancer Congress in Stockholm.)

Should that second anticipated analysis have the same results, the case would be sealed. “What I say right now is, I utilize [anti-EGFR therapy] as a salvage therapy option in select patients with G13D,” Dr. Grot concluded. “It’s not that common—about 8% of all patients who you might see and 18% of the KRAS mutant tumors.” ■


Related Articles

Standards of Care Confirmed in Latest Group of Colorectal Cancer Trials

Axel Grothey, MDColorectal cancer studies reported at this year’s ASCO meeting offered little in the way of practice-changing information, according to Axel Grothey, MD, of the Mayo Clinic in Rochester, Minnesota. But they did confirm existing standards of care, he noted at the Best of ASCO® meeting in Seattle.

SIDEBAR: Will Aflibercept Break Dry Spell in New Agents for Colorectal Cancer?

Promising results were recently presented from VELOUR, a second-line phase III trial comparing FOLFIRI (leucovorin, fluorouracil, irinotecan) with vs without aflibercept, a fusion protein that binds placental growth factor, VEGFA, and VEGFB.1 “This is an important trial because it might lead to the ...

SIDEBAR: Risk-based Approach Needed for Stage II Colorectal Cancer

Management of stage II colorectal cancer remains a considerable gray area where an individualized risk-based approach and more molecular research are needed, according to Axel Grothey, MD, of the Mayo Clinic in Rochester, Minnesota.

“Stage II is a little bit more complicated than stage III,” he...


Advertisement

Advertisement



Advertisement